The current investigation was intended to improve the assay strategy for concurrent estimation of telmisartan and atorvastatin by utilizing instrument high performance liquid chromatography (HPLC), mobile phase of methanol:water, and 250 nm detection wavelength. The retention times were established to be 2.4 minutes for telmisartan and 3 minutes for atorvastatin. The analytical technique for both the drugs showed linearity over the range of 20 to 80 ppm of the target concentration. The recuperation was seen as 99.9% for both drugs. Both system framework and strategy precision were seen as precise and well inside the range. The detection limit of 0.05 for telmisartan and 0.019 for atorvastatin was found. The planned method was found to be simple, explicit, specific, linear, and rugged. Hence, it can be utilized for routine examination of telmisartan and atorvastatin in mass bulk and pharmaceutical formulations.

The major limiting factor in doxorubicin’s long-term administration is the development of cumulative dosedependent cardiomyopathy and congestive heart failure. Also, doxorubicin causes deterioration in hepato-renal function. It significantly increases the levels of blood urea nitrogen, creatinine, alanine transaminase, and aspartate transaminase distortion in normal renal and hepatic histology. The present study was undertaken to find out the protective role of beta-caryophyllene (BCP), an anti-oxidant against doxorubicin-induced multiple organ toxicities in experimental animals. In this study, male Wistar rats were divided into four groups. The first group, control group, was administered with vehicle (2.5% tween 20); the second group received doxorubicin (15 mg/kg intraperitoneally at a single dose), third and fourth groups (treatment groups) received BCP plus doxorubicin (15 mg/kg) at doses of 100 mg/kg and 200 mg/kg respectively. BCP was given orally for 15 days and doxorubicin was given on 13th day of treatment. Cardiac function was assessed by measuring electrocardiogram changes and cardiac biomarkers—doxorubicin-induced significant lengthening of QT-interval and ST-elevation, which was completely prevented by BCP treatment. Doxorubicin caused oxidative stress as indicated by a significant decrease in reduced superoxide dismutase, glutathione level, and catalase activity with an increase in malondialdehyde compared to control. Doxorubicin and BCP significantly reversed these values compared to doxorubicin in heart, kidney, and liver. The histopathological examination has also shown signs of toxicity in doxorubicin treated groups, and healing effect was noticed in treatment groups.